Thursday, November 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Polestar Secures 950 Million in Funding for Ambitious Growth Plans

Elaine Mendonca by Elaine Mendonca
February 29, 2024
in Breaking News
0
Automotive Stock Market Today
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Polestar has recently secured a substantial $950 million in external funding from a group of 12 international banks. This funding, part of a three-year loan facility, will fuel the company’s ambitious growth plans. Geely Sweden Holdings has also pledged to support Polestar in future financing activities as needed.

The funds will primarily be used to drive the global rollout of two new SUV models, with the aim of boosting both volume and profit margins in the latter half of the year. Polestar is on track to achieve cash flow break-even by 2025, with progress already being made towards this goal through the expansion of its model range and increased sales worldwide.

Geely Holding Group CEO and Polestar Board Member, Daniel Li, highlighted Geely’s dedication to providing operational and financial backing to Polestar. This commitment includes ensuring access to cutting-edge technology and engineering expertise. The financing agreement is accompanied by an efficiency program that involves job cuts and other measures to strengthen Polestar’s overall business strategy.

With the new shareholder structure, Geely Sweden Holdings will become the second-largest shareholder in Polestar, while Volvo Cars will retain an 18% stake. This injection of funding represents a major milestone in Polestar’s journey, laying a solid foundation for future growth and expansion opportunities ahead.

PSNY Stock Gains 6.43% on February 28, 2024, Continuing Rise in After-Hours Trading

On February 28, 2024, PSNY stock showed some positive momentum as it closed the trading day with a 6.43% increase in price. The stock closed at $1.49, which was a $0.09 increase from the previous day’s closing price. Additionally, in after-hours trading, the stock continued to rise, gaining an additional $0.02.

PSNY Stock Performance Fluctuates on February 28, 2024: Total Revenue Sees 84.11% Increase

PSNY has seen fluctuations in stock performance on February 28, 2024. Total revenue for the year was $2.46 billion, an 84.11% increase from the previous year. Third-quarter revenue was $613.18 million, a 10.52% decrease from the previous quarter. Net income for the year was -$465.79 million, a 53.77% improvement from the previous year. Third-quarter net income was -$155.37 million, a 48.9% increase from the previous quarter. Earnings per share data is currently unavailable. The company is facing challenges in financial performance, and investors should monitor future earnings reports and updates.

Tags: PSNY
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post

Virios Therapeutics Advancing Antiviral Therapies for Chronic Illnesses

Finance_Financialization

BMO Capital Analyst Reaffirms Republic Services with Market Perform Rating and Raises Price Target

Finance_Fiscal (3)

JP Morgan Analyst Upgrades Axon Enterprise to Overweight with 330 Price Target

Recommended

Baidu Stock

Baidu’s Strategic Moves in Autonomous Driving and AI Draw Mixed Investor Reactions

1 month ago

Windtree Therapeutics Achieves Financial Stability and Advances Clinical Programs

2 years ago
Technology Data analytics Stock Bull Market

Anticipation High for Adobes FirstQuarter Financial Results and AI Innovation

2 years ago
Ideaya Biosciences Stock

Ideaya Biosciences: A Tale of Market Skepticism and Clinical Promise

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

Is Darden Restaurants Facing a Critical Test?

Critical Juncture for USA Rare Earth as Earnings and Chinese Export Curbs Collide

AES Shares Surge on Potential $38 Billion Acquisition Speculation

Kura Oncology Investors Await Crucial FDA Verdict

Cadence Design Stock: A Battle Between Fundamentals and Market Signals

Trending

DuPont de Nemours Stock
Analysis

DuPont Faces Critical Test as Quarterly Results Loom

by Dieter Jaworski
November 6, 2025
0

DuPont de Nemours finds itself at a pivotal moment as the chemical giant prepares to release quarterly...

Sarepta Therapeutics Stock

Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure

November 6, 2025
Emerson Electric Stock

Emerson Electric’s Strategic Pivot Faces Market Scrutiny

November 6, 2025
Lanzatech Global Stock

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

November 6, 2025
Darden Restaurants Stock

Is Darden Restaurants Facing a Critical Test?

November 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • DuPont Faces Critical Test as Quarterly Results Loom
  • Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure
  • Emerson Electric’s Strategic Pivot Faces Market Scrutiny

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com